Objective: The correlation of HbA1c level with mortality in patients with ischemic stroke and Paroxysmal Atrial Fibrillation (pAfib).

Method: 278 patients with medical history of ischemic stroke and pAfib confirmed with cerebral Computed Tomography and electrocardiogram or rhythm Holter respectively, were included in the study. All patients visited for routine health screening examination or with minor deseases the departments of internal medicine of three tertiary hospitals. The mean age was 78±12 years. The participants were divited into two groups: In group A, 167 patients (60%) that had diabetes mellitus type II (DMT2) were included. Among them, 92 were women (55%) and 75 were men (45%). The remaining 111 patients (58 women (52%) and 53 men (48%)) had no medical history of DMT2, and were included in group B. Among others, HbA1c was measured in all patients in months 6,12,18,24,36 and a survival/ events follow-up was recorded. The study duration was 36 months.

Results: In group A, 20 deaths of patients (12%) were reported, among them 8 were men (40%) and 12 were women (60%) with average HbA1c measurements during the follow-up period: 2 patients (10%) with 6,5<HbA1c<7, 6 patients (30%) with 7<HbA1c<8,5 and 12 patients (60%) with HbA1c>8,5. In group B, 10 deaths (9%) were reported. Among them, 4 men (40%) and 5 women (60%) with measurement 6<HbA1c<6,5 and 1 woman (10%) with HbA1c<6. The mortality for patients with ischemic stroke and pAfib is increased with the increase of HbA1c in patients with DMT2 in a statistically significant manner (p 0.0031). An non-statistically significant increase in mortality was also observed in group B. (p 0.22).

Conclusion: The increase in the level of HbA1c increases the mortality in patients with ischemic stroke and pAfib especially in those with DMT2.


K. Kanellopoulou: None. I.L. Matsoukis: None. A. Ganotopoulou: None. T. Athanasopoulou: None. C. Triantafillopoulou: None. A. Sianni: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.